LEUPROLIDE
Ependymoma
St. Jude Children's Research Hospitalprotein_peptidePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
20 Active assets in the Ependymoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab University of Florida | Phase 2 | BB |
Olaparib Fundación de investigación HM | Phase 2 | BB |
Indoximod Theodore S. Johnson | Phase 2 | B |
Cyclophosphamide Theodore S. Johnson | Phase 2 | B |
ETOPOSIDE Theodore S. Johnson | Phase 2 | B |
View all 35 →
Same molecule, other indications
LEUPROLIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →